ezetimiba/simvastatina tevagen 10 mg/40 mg comprimidos efg
teva pharma s.l.u. - simvastatina; ezetimiba - comprimido - 40 mg/10 mg - simvastatina 40 mg; ezetimiba 10 mg - simvastatina y ezetimiba
ezetimiba/simvastatina pharma combix 10 mg/40 mg comprimidos efg
laboratorios combix s.l.u. - simvastatina; ezetimiba - comprimido - 10 mg/40 mg - simvastatina 10 mg; ezetimiba 40 mg - simvastatina y ezetimiba
ezetimiba/simvastatina tecnigen 10 mg/20 mg comprimidos efg
tecnimede espana industria farmaceutica s.a. - simvastatina; ezetimiba - comprimido - 20 mg/10 mg - simvastatina 20 mg; ezetimiba 10 mg - simvastatina y ezetimiba
ezetimiba/simvastatina tecnigen 10 mg/40 mg comprimidos efg
tecnimede espana industria farmaceutica s.a. - simvastatina; ezetimiba - comprimido - 40 mg/10 mg - simvastatina 40 mg; ezetimiba 10 mg - simvastatina y ezetimiba
ezetimibe/simvastatin teva 10mg/10mg tableta
teva pharmaceuticals cr, s.r.o., praha array - 16227 ezetimib; 10647 simvastatin - tableta - 10mg/10mg - simvastatin a ezetimib
ezetimibe/simvastatin teva 10mg/20mg tableta
teva pharmaceuticals cr, s.r.o., praha array - 16227 ezetimib; 10647 simvastatin - tableta - 10mg/20mg - simvastatin a ezetimib
ezetimibe/simvastatine teva 10 mg/20 mg, tabletten
teva nederland b.v. swensweg 5 2031 ga haarlem - ezetimib ; simvastatine - tablet - butylhydroxyanisol (e 320) ; cellulose, microkristallijn (e 460) ; citroenzuur 1-water (e 330) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; magnesiumstearaat (e 470b) ; propylgallaat (e 310), - simvastatin and ezetimibe
ezetimibe/simvastatine teva 10 mg/40 mg, tabletten
teva nederland b.v. swensweg 5 2031 ga haarlem - ezetimib ; simvastatine - tablet - butylhydroxyanisol (e 320) ; cellulose, microkristallijn (e 460) ; citroenzuur 1-water (e 330) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; magnesiumstearaat (e 470b) ; propylgallaat (e 310), - simvastatin and ezetimibe
ezetimibe/simvastatine teva 10 mg/80 mg, tabletten
teva nederland b.v. swensweg 5 2031 ga haarlem - ezetimib ; simvastatine - tablet - butylhydroxyanisol (e 320) ; cellulose, microkristallijn (e 460) ; citroenzuur 1-water (e 330) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; magnesiumstearaat (e 470b) ; propylgallaat (e 310), - simvastatin and ezetimibe
nna-ezetimibe/simvastatin 10/40 ezetimibe 10 mg and simvastatin 40 mg tablet blister pack
arrotex pharmaceuticals pty ltd - simvastatin, quantity: 40 mg; ezetimibe, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; butylated hydroxyanisole; hypromellose; iron oxide black; microcrystalline cellulose; propyl gallate; ascorbic acid; iron oxide yellow; croscarmellose sodium; citric acid; magnesium stearate; iron oxide red - adults (?18 years),prevention of cardiovascular disease apo-ezetimibe/simvastatin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see clinical trials).,primary hypercholesterolaemia apo-ezetimibe/simvastatin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate: ? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh) apo-ezetimibe/simvastatin is indicated in patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis). children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post- menarche),heterozygous familial hypercholesterolaemia (hefh) apo-ezetimibe/simvastatin is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate: ? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh) apo-ezetimibe/simvastatin is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).